based on WHO classification, among which "pure" GH cell adenomas are divided into two distinct subtypes ultrastructurally: densely granulated somatotroph (DG-type) adenomas with large and dense secretory granules in the cytoplasm and sparsely granulated somatotroph (SG-type) adenomas with small and sparse granules.
One of the typical microscopic features of SG-type adenomas is inclusion body called "fibrous body" composed of aggregated cytokeratin filaments. By immunostaining with anti-cytokeratin antibody (CAM5.2), SG-type adenomas show a dot-like distribution pattern in the cells, whereas DG-type adenomas show a perinuclear (ring-like) pattern in the cells.
It has been reported that SG-type adenomas occur more frequently at younger age, are less responsive to the evaluation of the drug responsiveness, 100 µg octreotide (Sandostatin ® , Sandoz, Switzerland) or 2.5 mg bromocriptin (Parodel ® , Novartis, Switzerland) was administrated subcutaneously or orally; the percentage of GH suppression after administration of octreotide or bromocriptin was calculated.
Analysis of tissue specimens
Tissue specimens obtained during transsphenoidal surgery from each pituitary tumor were used. A portion of the tissue specimens was immediately frozen with RNAlater ® (Ambion Inc., Austin, TX, USA) and stored at −80°C for quantification of mRNA. The remaining tissue specimens were subjected to histological and immunohistochemical studies.
Quantification of mRNA
Total RNA was extracted from pituitary tumor using QIAzol (Qiagen, Chatsworth, CA) and 5 µg of total RNA was reverse transcribed with a first-strand cDNA synthesis kit (GE Healthcare, Chalfont, Buckinghamshire, UK), as previously reported [5] . The samples that resulted in lower quality of RNA and/or cDNA were eliminated from the study. Thirty-six samples (19 DG, 17 SG-type adenomas) were used for subsequent evaluation of gene expression. mRNA expression of genes were quantified by TaqMan fluorescence methods using a QuantiTect Probe PCR kit (Qiagen) and a Chromo4™ Multicolor Real-Time PCR Detection System (Bio-Rad Laboratories, Japan). Universal Probe Library system (Roche, Nutley, New Jersey, USA) combined with TaqMan technology, which prevents generation of nonspecific amplification products, were used to quantify the expression of the following genes: somatostatin receptor subtype 2 and 5 (SSTR2, SSTR5), Dopamine D2 receptor (D2R) and glyceraldehyde-3-phosphate and dehydrogenase (GAPDH). After reverse transcription, the reaction mixtures were denatured at 95°C for 3min followed by 40 cycles of PCR at 95°C for 30s, 58°C for 30s, 72°C for 30s. The PCR primers of the genes were synthesized by Griner bio-one (Tokyo, Japan) and their sequences were shown in Table 1 . Fluorescence data were quantitatively analyzed by including serial dilutions of control samples in each reaction to produce a standard curve. To compare the relative expression of each gene, GAPDH was used as an endogenous internal control and the relative expression of each mRNA to that of GAPDH were calculated. thyrotropin-releasing hormone (TRH) and growth hormone-releasing hormone (GRH), are more resistant to octreotide or bromocriptin, and are larger in size and more invasive than DG-type adenomas [2] [3] [4] . Despite the differences of morphological, clinical and hormonal features between these subtypes, the molecular mechanisms underlying these features remain unknown.
To clarify the mechanisms of differences in drug responsiveness between the two subtypes, we investigated the differential expression profiles of genes related to drug responsiveness such as SSTR2, SSTR5 and D2R between the two subtypes.
Patients and methods

Patients
Surgically removed pituitary adenomas from acromegaly patients who admitted to Toranomon Hospital were used. This study was approved by the institutional ethical review committee, and informed consent was obtained from each patient before surgery. All patients were diagnosed as acromegaly based on the clinical manifestation, increased serum GH and IGF-1 levels with lack of serum GH suppression after oral glucose tolerance test, and the presence of pituitary tumors demonstrated by diagnostic magnetic resonance image. "Pure" GH cell adenomas were confirmed by immunohistochemical study after excluded adenomas containing 5% or more prolactin (PRL) positive cells. Pure GH cell adenomas were classified into the two subtypes (DG-type or SG-type) based on cytokeratin distribution pattern in the cytoplasm, as reported [4] . Briefly, the adenoma composed of over 70% perinuclear pattern cells or less than 8% dot pattern cells was categorized as "DG-type." The adenoma composed of over 70% dot pattern cells was categorized as "SG-type." The other adenomas, which did not fall into either of these two categories, were categorized as "intermediate type."
Endocrinological and imaging studies
Basal plasma GH and IGF-1 levels represent the mean ± SEM of at least three separated samples obtained in the morning after overnight fasting. The size and cavernous sinus invasion of tumors were determined by the neuroimaging. Tumors that were larger than 10 mm in diameter were categorized into macroadenoma, and tumors that were equal to or smaller than 10 mm in diameter were categorized into microadenoma. For between groups were examined for statistical significance using Kruskal-Wallis test with Dunn's post hoc test. Their relations between two continuous variables were evaluated using Spearmann's rank correlation coefficient. P values < 0.05 were considered statistically significant. All statistical analyses were performed using Windows software Prism 5.0 (GraphPad Software, CA, USA).
results
Patient's profiles
Pure GH cell adenomas resected from 82 patients were categorized 44 (23 males and 21 females, aged 48.6 ± 2.0 years) as DG-type and 38 (17 male and 21 females, aged 40.8 ± 1.8 years) as SG-type. As shown in Table 2 , patients with SG-type adenoma were significantly younger in age than DG-type adenoma. There were no significant differences in gender between the two subtypes of adenomas.
The total number of available data on tumor size and cavenous sinus invasion were 74 (38 DG-type, 36 SG-type) and 76 (41 DG-type, 35 SG-type), respectively. Twenty-seven out of 38 DG-type adenomas (71.1%) and 34 out of 36 SG-type adenomas (94.4%) were macroadenomas. Fourteen out of 41 DG-type adenomas (34.1%) and 20 out of 35 SG-type adenomas (57.1%) represented cavernous sinus invasion. These results showed that SG-type adenomas were significantly bigger and more invasive than DG-type adenomas.
Immunohistochemical study
Immunohistochemical study was performed by the avidin-biotin-peroxidase complex (ABC) technique as reported. The specific antibodies used in this study were a monoclonal antibody to cytokeratin (CAM5.2, Becton-Dickinson, Mountain View, USA), human GH (Dakopatts, Glostrup. Denmark), PRL (Immuno Tech. France) and SSTR2 (SS-800, Gramsch Lab. Germany). Hematoxylin was used as counterstain. The percentage of cell staining of SSTR2 was evaluated semi-quantitatively as follows; (−) negative staining, (1+) <20%, (2+) 20-50%, (3+) >50%, respectively. The resulting sections were examined blind, without any prior knowledge of subtype by single observer.
Statistical analyses
Data were shown as mean ± SEMs. Differences 2.6-fold greater than those in SG-type adenomas (p < 0.05). Whereas SSTR5 mRNA expression did not differ between the two subtypes (p = 0.44). D2R mRNA expression in DG-type adenomas were about 2.0-fold (p < 0.005) lower than in SG-type adenomas.
Correlation between gene expression and drug responsiveness
Percentage of GH suppression by octreotide showed a significant positive correlation with SSTR2 mRNA expression (r = 0.54, P < 0.005) ( Fig. 3) but not with SSTR5 (data not shown). There was no significant correlation between percentage of GH suppression by bromocriptin and D2R mRNA expression (r = -0.32, P = 0.31).
There were no significant differences of basal GH and IGF-1 levels between the two subtypes. The total number of available data on GH suppression by octreotide and bromocriptin were 57 (29 DG-type, 28 SG-type) and 56 (27 DG-type, 29 SG-type), respectively. GH suppression by octreotide, but not by bromocripitin in DG-type adenoma was significantly greater than that in SG-type adenoma ( Table 2 , Fig. 1) .
Expression profiles of genes related to drug responsiveness
Among tumor specimens from the above 82 patients, 36 samples (19 DG-, 17 SG-type adenomas) were used for subsequent analysis of gene expression. We evaluated the expression of genes related to drug responsiveness including SSTR2, SSTR5 and D2R (Fig. 2) . SSTR2 mRNA expression in DG-type adenomas were about 
Immunohistochemistry and protein level
Among the 36 tumor specimens used for gene expression analysis, 34 were available for following immunohistochemical study (18 DG-type, 16 SG-type). Typical staining pattern of cytokeratin and SSTR2 in DG-and SG-type adenomas were shown in Fig. 4 . As shown in Table 3 , positive immunostaining cells for SSTR2 in DG-type was observed in 16 out of 18 (89%) in DG-type and 2 out of 16 (13%) in SG-type. Based on the immunohistochemical semi-quantitative grading score (Table 3) , relative mRNA expression in (2+) group was significantly (P < 0.05) greater than that in (−) group (Fig. 5 ).
Discussion
The present study showed the differences of clinical and hormonal features between DG-and SG-type somatotroph adenomas, and further revealed for the first time the differential expression of genes related to drug responsiveness between the twosubtypes.
Clinical characteristics demonstrated in the present study are consistent with the previous reports, showing that SG-type adenomas were more frequent in younger age, larger, more invasive and less responsive to octreotide than DG-type [2, 4] , although responsiveness to bromocriptin between the two subtypes were com- The percentage of cells staining sstr2A was evalutaed as follows: (-) negative staining, (+) <20%, (2+) 20-50%, (3+) >50%. DG: densely granulated somatotroph adenoma, SG: sparsely granulated somatotroph adenoma responsiveness to octreotide between DG-and SG-type adenomas are related to the amount of SSTR2 rather than SSTR5, expressed on the cells of each subtype somatotroph adenomas. Pasireotide (SOM230), a new SSA with higher affinity to SSTR5, than to SSTR2, might be more effective medical treatment for SG-type adenomas than DG-type adenomas.
Although dopamine agonists (DAs) were less effective than SSAs in lowering GH and IGF-I in treatment of somatotropinomas, DAs can be orally administered at lower costs than SSAs. It has been reported that the suppression of GH/PRL by D2R agonists was correlated to D2R gene expression in lactotroph and somatotroph tumors in vitro [20, 21] . In the present study, however, no significant differences were detected in responsiveness to bromocriptin between the two subtypes, despite the greater expression of D2R in SG type than DG-type adenomas. Recently, it was reported that heterodimerization of D2R/SSTR2 was associated with a reciprocal modification of ligand binding and increased internalization of SSTR2 [22, 23]. Thus, it is possible that high expression of D2R promotes desensitization of SSTR2 and D2R and octreotide responsiveness on SG-type adenomas.
In conclusion, the present study strongly suggests that SSTR2 expression is involved in determine difference in responsiveness to octreotide between the two distinct subtypes (DG-and SG-) of "pure" somatotroph adenomas. Further studies are required to clarify the whole picture of molecular mechanism underlying the clinical differences between DG-and SG-type adenomas.
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parable.
The primary treatment of acromegaly is surgical excision of the somatotroph adenomas by transsphenoidal approach. However, medical treatment of acromegaly with somatostatin analogues (SSA), such as octreotide, is first-line therapy for patients who cannot tolerate surgery or who have residual tumor after surgery. Although octreotide has antisecretory and antiproliferative effects on the somatotroph adenomas, only 50−70% of patients achieve biochemical control by this treatment [6, 7] . The response to octreotide depends on the expression of SSTR2 on the tumor cells, because octreotide binds with higher affinity to SSTR2 among several SSTR subtypes [8] [9] [10] [11] [12] . Among five subtypes of SSTR, SSTR2 and SSTR5 are the most dominant isoforms expressed in pituitary adenomas [12] [13] [14] .
Several studies have shown a positive correlation between GH suppression by octreotide and SSTR2 and/or SSTR5 expression in GH-secreting adenomas [15] [16] [17] [18] [19] , however to date no studies on differences of SSTR2 and SSTR5 expression between DG-and SG-type adenomas by using quantitative real-time RT-PCR has been reported. The present study revealed for the first time a significant greater SSTR2, but not SSTR5 expression in DG-type adenomas than SG-type adenomas. Furthermore, a positive correlation between the SSTR2 expression and octreotide responsiveness was observed. These results suggest that the different 
